Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director · President and CEO | January 06, 2026 | January 08, 2026 |
| Surface Oncology, Inc.SURF · Entity 109857 | Director | June 28, 2022 | June 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 323,530 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Sale · Disposed 23,766 · Balance 323,530 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
Surface Oncology, Inc.
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2032-06-28 | Direct | 48,000 |
Reported balance
After 2022-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-28 · Grant · Acquired 48,000 · Balance 48,000 F1: 50% of the Options shall vest on June 28, 2023, and the remainder of the Options shall vest in equal monthly installments over the following twelve months, such that all of the Options shall be vested on June 28, 2024, subject to the Reporting Person's continued service relationship with the Company on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the Options shall vest on June 28, 2023, and the remainder of the Options shall vest in equal monthly installments over the following twelve months, such that all of the Options shall be vested on June 28, 2024, subject to the Reporting Person's continued service relationship with the Company on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2021 Filed Oct 15, 2021 18:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 15,313 | $4.39 | $67,224.07 |
DisclosureSEC source: 0001453687-21-000141 · wf-form4_163433561231518.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,759 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.35 to $4.475. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 16:25 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000132 · wf-form4_163346550161233.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,072 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 75,000 shares of the Issuer's common stock (the "Performance RSUs"), which may be earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. Any Performance RSUs will generally vest in two equal installments upon the dates of achievement of each of the two performance conditions, subject to continued employment, so long as each performance condition is met before December 31, 2021. The compensation committee of the board of directors of the Issuer has determined that the first of the performance conditions has been met, and accordingly 37,500 Performance RSUs vested on October 1, 2021. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 16:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 163,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001453687-21-000120 · wf-form4_163286110389016.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 163,000 shares Expires 2031-09-23 F2 · derivative.exercise_date: This option vests as to 25% on September 24, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 16:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000120 · wf-form4_163286110389016.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,572 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on September 24, 2022. The remainder of the underlying shares will vest in three equalannual installments thereafter so that the underlying shares will be fully vested on September 24, 2025. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 16:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,523 | $4.51 | $20,398.73 |
DisclosureSEC source: 0001453687-21-000107 · wf-form4_163070026398370.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,372 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.4707 to $4.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000107 · wf-form4_163070026398370.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,688 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000107 · wf-form4_163070026398370.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 16:30 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,806 | $4.38 | $21,040.67 |
DisclosureSEC source: 0001453687-21-000081 · wf-form4_162275218310282.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,958 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.34 to $4.385. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:30 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000081 · wf-form4_162275218310282.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:30 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000081 · wf-form4_162275218310282.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 17:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 5,461 | $4.26 | $23,257.31 |
DisclosureSEC source: 0001453687-21-000023 · wf-form4_161481004616254.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,826 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.24 to $4.285. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000023 · wf-form4_161481004616254.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,563 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000023 · wf-form4_161481004616254.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 670,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001453687-21-000014 · wf-form4_160996973826334.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,000 Underlying: Common Stock · 670,000 shares Expires 2031-01-03 F2 · derivative.exercise_date: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000014 · wf-form4_160996973826334.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,350 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 16:22 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,323 | $3.35 | $11,134.04 |
DisclosureSEC source: 0001453687-20-000131 · wf-form4_160703055313759.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,350 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.335 to $3.375. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 16:22 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000131 · wf-form4_160703055313759.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 16:22 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000131 · wf-form4_160703055313759.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 16:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,364 | $2.39 | $8,034.58 |
DisclosureSEC source: 0001453687-20-000103 · wf-form4_159916495956344.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,735 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.36 to $2.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000103 · wf-form4_159916495956344.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,438 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000103 · wf-form4_159916495956344.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 16:10 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001104659-20-081208 · a4.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: This option will vest as to 25% on July 1, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 16:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,253 | $3.86 | $12,556.91 |
DisclosureSEC source: 0001453687-20-000054 · wf-form4_159121693539654.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,162 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.83 to $3.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 16:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000054 · wf-form4_159121693539654.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,375 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 16:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000054 · wf-form4_159121693539654.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 16:25 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,374 | $3.86 | $13,011.49 |
DisclosureSEC source: 0001453687-20-000021 · wf-form4_158327072572666.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,477 F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.85 to $3.87. The Reporting Person undertakes to provide upon request to theSEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:25 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000021 · wf-form4_158327072572666.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,313 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:25 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000021 · wf-form4_158327072572666.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:06 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000009 · wf-form4_157835918962071.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 16:20 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 14,272 | $1.53 | $21,809.04 |
DisclosureSEC source: 0001453687-19-000168 · wf-form4_157540798248948.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,914 F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.50 to $1.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 16:20 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-19-000168 · wf-form4_157540798248948.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 43,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: These restricted stock units vested as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: These restricted stock units vested as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 16:20 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-19-000168 · wf-form4_157540798248948.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 16:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001453687-19-000145 · wf-form4_157065234617939.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-10-06 F1 · derivative.exercise_date: This option shall vest as to 50% of the shares on October 7, 2020, and the remaining 50% of the shares on October 7, 2021. Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 16:31 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 41,436 | $1.81 | $74,999.16 |
DisclosureSEC source: 0001453687-19-000121 · wf-form4_156633307237124.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,436 Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:30 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001760229-19-000002 · wf-form4_155130300495416.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2029-02-24 F1 · derivative.exercise_date: This option will vest as to 25% on February 25, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2018 Filed Dec 3, 2018 08:39 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantRestricted Stock Units · Derivative | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410578-18-000585 · a4.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| December 01, 2018 Filed Dec 3, 2018 08:39 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001410578-18-000585 · a4.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-30 F1 · derivative.exercise_date: This option vests as to 25% on December 1, 2019. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.